Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Relevant for patients whose systemic inflammation has a gut-driven component
These users report appreciating treatment benefits while active but watching improvements gradually fade over months post-discontinuation, with timeline showing first 2 months maintaining most benefits creating initial optimism, months 2-4 showing noticeable decline returning toward baseline, months 4-8 continuing regression approaching pre-treatment status, and stabilization occurring 60-80% back toward original baseline with only modest long-term improvement retention
Consult the Safety Data Sheet for full handling guidance
Safety concerns include risk of intramuscular injection (causing faster absorption and potential adverse reactions), intradermal administration (incomplete delivery), and injection-site reactions or lipohypertrophy from repeated injections in the same small area
